{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T05:18:21Z","timestamp":1787807901884,"version":"build-2784847793"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Alectinib is the standard first-line therapy for treatment-na\u00efve ALK-positive non-small cell lung cancer (NSCLC). Given its increasing clinical utilization, a comprehensive pharmacovigilance evaluation of its adverse events (AEs) is warranted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We assessed alectinib-associated AEs using the FDA Adverse Event Reporting System (FAERS) database from Q4 2015 to Q3 2025. AEs were categorized per MedDRA, and four disproportionality analysis algorithms were used to detect potential safety signals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 8,602 reports with alectinib as the primary suspect drug were included. Overall, 51.1% were serious adverse events (SAEs). Median AE onset was 120 days (IQR: 27\u2013428), with 27.4% within 30 days and 28.9% after 360 days. All algorithms identified 108 preferred terms meeting positive safety signal criteria. Besides well-recognized AEs, novel signals emerged: hypertriglyceridemia, hypercholesterolemia, pericardial effusion, erythema multiforme, muscle fatigue, and myositis. Multivariate regression showed male sex and age \u226565 years were independently linked to higher SAE risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Leveraging a large pharmacovigilance database, this study comprehensively characterized alectinib's safety profile. It confirmed established signals and uncovered novel potential AEs needing further prospective research. Subgroup disparities and key monitoring windows were identified, deepening mechanistic understanding and supporting optimized clinical risk mitigation strategies. It should be noted that disproportionality analysis is used to detect potential safety signals rather than establishing causal relationships, and all identified signals require further clinical evaluation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1894585","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T04:27:51Z","timestamp":1787804871000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world safety profile of alectinib: a 10-year pharmacovigilance study based on the FDA adverse event reporting system"],"prefix":"10.3389","volume":"13","author":[{"given":"Le","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The Second Affiliated Hospital of Army Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DanDan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Second Affiliated Hospital of Army Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ChenJing","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Second Affiliated Hospital of Army Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Second Affiliated Hospital of Army Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Second Affiliated Hospital of Army Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Second Affiliated Hospital of Army Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Second Affiliated Hospital of Army Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.cell.2007.11.025","article-title":"Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer","volume":"131","author":"Rikova","year":"2007","journal-title":"Cell."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N Engl J Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"497","DOI":"10.6004\/jnccn.2022.0025","article-title":"Non-small cell lung cancer, version 3","volume":"20","author":"Ettinger","year":"2022","journal-title":"J Natl Compr Canc Netw."},{"key":"B6","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.annonc.2019.10.026","article-title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS","volume":"31","author":"Park","year":"2020","journal-title":"Ann Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1200\/JCO-25-01061","article-title":"Therapy for stage IV Non-small cell lung cancer with driver alterations: ASCO living guideline, version 2025","volume":"43","author":"Reuss","year":"2025","journal-title":"J Clin Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.annonc.2025.09.018","article-title":"Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX study","volume":"37","author":"Peters","year":"2026","journal-title":"Ann Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S2213-2600(19)30053-0","article-title":"Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study","volume":"7","author":"Zhou","year":"2019","journal-title":"Lancet Respir Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","article-title":"Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial","volume":"390","author":"Hida","year":"2017","journal-title":"Lancet."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1016\/j.jtho.2021.07.008","article-title":"Blood first assay screening trial (BFAST) in treatment-naive advanced or metastatic NSCLC: initial results of the phase 2 ALK-positive cohort","volume":"16","author":"Dziadziuszko","year":"2021","journal-title":"J Thorac Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1056\/NEJMoa2310532","article-title":"Alectinib in resected ALK-positive non-small-cell lung cancer","volume":"390","author":"Wu","year":"2024","journal-title":"N Engl J Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1016\/j.jtho.2017.06.070","article-title":"Pooled systemic efficacy and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer","volume":"12","author":"Yang","year":"2017","journal-title":"J Thorac Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e71352","DOI":"10.1002\/cam4.71352","article-title":"Real-world pharmacovigilance study of fruquintinib based on the FDA adverse event reporting system (FAERS) database","volume":"14","author":"Xu","year":"2025","journal-title":"Cancer Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3390\/toxics13030210","article-title":"Safety profile and hepatotoxicity of anaplastic lymphoma kinase tyrosine kinase inhibitors: a disproportionality analysis based on FDA adverse event reporting system database","volume":"13","author":"Yang","year":"2025","journal-title":"Toxics"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1169735","DOI":"10.3389\/fimmu.2023.1169735","article-title":"Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system","volume":"14","author":"Shu","year":"2023","journal-title":"Front Immunol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"17588359241306940","DOI":"10.1177\/17588359241306940","article-title":"Sex differences in patients with Non-Small Cell Lung Cancer harboring driver fusions treated with tyrosine kinase inhibitors: a systematic review","volume":"16","author":"Leporati","year":"2024","journal-title":"Ther Adv Med Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"100700","DOI":"10.1016\/j.jtocrr.2024.100700","article-title":"Alectinib versus crizotinib in Asian patients with treatment-naive advanced ALK-positive NSCLC: five-year update from the phase 3 ALESIA study","volume":"5","author":"Zhou","year":"2024","journal-title":"J Thorac Oncol Clin Res Rep."},{"key":"B20","doi-asserted-by":"publisher","first-page":"101560","DOI":"10.1016\/j.esmoop.2023.101560","article-title":"Expert consensus of management of adverse drug reactions with anaplastic lymphoma kinase tyrosine kinase inhibitors","volume":"8","author":"Zhou","year":"2023","journal-title":"ESMO Open."},{"key":"B21","doi-asserted-by":"publisher","first-page":"6219","DOI":"10.2147\/DDDT.S523455","article-title":"Magnesium isoglycyrrhizinate alleviates alectinib-induced hepatotoxicity by inhibiting mitochondrial damage-mediated pyroptosis","volume":"19","author":"Chen","year":"2025","journal-title":"Drug Des Devel Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e245011","DOI":"10.1136\/bcr-2021-245011","article-title":"Bilateral vocal cord paralysis due to direct invasion of right and left recurrent laryngeal nerves in a small cell lung cancer patient","volume":"14","author":"Horiuchi","year":"2021","journal-title":"BMJ Case Rep"},{"key":"B23","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.lungcan.2014.07.020","article-title":"Metastatic sites and survival in lung cancer","volume":"86","author":"Riihimaki","year":"2014","journal-title":"Lung Cancer."},{"key":"B24","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s10637-022-01242-6","article-title":"Toxicity profile of anaplastic lymphoma kinase tyrosine kinase inhibitors for patients with non-small cell lung cancer: a systematic review and meta-analysis","volume":"40","author":"Tao","year":"2022","journal-title":"Invest New Drugs."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1177\/1078155220904141","article-title":"Life-threatening hypertriglyceridemia-induced pancreatitis related to alectinib successfully treated by plasmapheresis: a review of the literature on metabolic toxicities associated with anaplastic lymphoma kinase inhibitors","volume":"26","author":"Rao","year":"2020","journal-title":"J Oncol Pharm Pract."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2265939","DOI":"10.1080\/07853890.2023.2265939","article-title":"Comprehensive review on the pathogenesis of hypertriglyceridaemia-associated acute pancreatitis","volume":"55","author":"Qiu","year":"2023","journal-title":"Ann Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.jtho.2023.03.020","article-title":"Analysis of serious weight gain in patients using alectinib for ALK-positive lung cancer","volume":"18","author":"de Leeuw","year":"2023","journal-title":"J Thorac Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e99","DOI":"10.1016\/j.jtho.2023.07.014","article-title":"Approach to Alectinib-induced body weight gain in patients with ALK+ non-small lung cancer","volume":"18","author":"Dingemans","year":"2023","journal-title":"J Thorac Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/cpdd.296","article-title":"Effect of food and esomeprazole on the pharmacokinetics of alectinib, a highly selective ALK inhibitor, in healthy subjects","volume":"6","author":"Morcos","year":"2017","journal-title":"Clin Pharmacol Drug Dev."},{"key":"B30","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.lungcan.2022.08.008","article-title":"Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trial","volume":"172","author":"Felip","year":"2022","journal-title":"Lung Cancer."},{"key":"B31","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1159\/000453314","article-title":"Alectinib-induced erythema multiforme and successful rechallenge with alectinib in a patient with anaplastic lymphoma kinase-rearranged lung cancer","volume":"9","author":"Kimura","year":"2016","journal-title":"Case Rep Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.2169\/internalmedicine.7472-21","article-title":"Severe skin toxicity caused by sequential anti-PD-1 antibody and alectinib in non-small-cell lung cancer: a report of two cases and a literature review","volume":"61","author":"Nishiyama","year":"2022","journal-title":"Intern Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jaccao.2022.09.006","article-title":"Cardiac toxicity of alectinib in patients with ALK+ lung cancer: outcomes of cardio-oncology follow-up","volume":"5","author":"Pruis","year":"2023","journal-title":"JACC CardioOncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s00280-017-3253-5","article-title":"Effect of alectinib on cardiac electrophysiology: results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studies","volume":"79","author":"Morcos","year":"2017","journal-title":"Cancer Chemother Pharmacol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"177527","DOI":"10.1016\/j.ejphar.2025.177527","article-title":"Alectinib causes sinus bradycardia by suppressing L-type calcium current in sinus node","volume":"998","author":"Liu","year":"2025","journal-title":"Eur J Pharmacol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40959-024-00207-3","article-title":"Pericardial effusion in oncological patients: current knowledge and principles of management","volume":"10","author":"Mori","year":"2024","journal-title":"Cardiooncology."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000548896","article-title":"Sex differences in cardiotoxicity of anaplastic lymphoma kinase inhibitors: an analysis of the FDA adverse event reporting system","volume":"104","author":"Asano","year":"2025","journal-title":"Oncology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.pathol.2020.10.023","article-title":"Alectinib induces marked red cell spheroacanthocytosis in a near-ubiquitous fashion and is associated with reduced eosin-5-maleimide binding","volume":"53","author":"Kuzich","year":"2021","journal-title":"Pathology."},{"key":"B39","doi-asserted-by":"publisher","first-page":"518","DOI":"10.3390\/curroncol30010041","article-title":"Successful treatment with Brigatinib after alectinib-induced hemolytic anemia in patients with metastatic lung adenocarcinoma-A case series","volume":"30","author":"El Sayed","year":"2022","journal-title":"Curr Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"711","DOI":"10.2169\/internalmedicine.1286-22","article-title":"Alectinib-induced hemolytic anemia with positive direct antiglobulin test in a patient with lung adenocarcinoma: a possible drug-drug interaction effect","volume":"63","author":"Isomura","year":"2024","journal-title":"Intern Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1097\/MPH.0000000000003003","article-title":"Hemolytic anemia with acanthocytes during alectinib treatment of anaplastic T-cell lymphoma: a case report and literature review","volume":"47","author":"Boumeghar","year":"2025","journal-title":"J Pediatr Hematol Oncol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1894585\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T04:27:52Z","timestamp":1787804872000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1894585\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":41,"alternative-id":["10.3389\/fmed.2026.1894585"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1894585","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"article-number":"1894585"}}